On December 18, 2024, MetaVia announced positive topline results from the Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The results showed a statistically significant decrease in alanine aminotransferase (ALT) levels, the trials primary outcome, for DA-1241 100 mg at weeks 4 and 8 and statistically significant results were also seen in controlled attenuation parameter (CAP) and hemoglobin A1c. DA-1241 was well tolerated with only 35% of patients on the 100 mg dose reporting a treatment related adverse event (TEAE) compared to 28% on placebo. The company is continuing to evaluate the data and will report additional results, including MRI-PDFF and other exploratory endpoints, in 2025. The company is looking into combination therapy with an advanced compound to help move DA-1241 into late stage trials.
